| abstract |
A method of inhibiting or resulting in activity of an integrin receptor comprising contacting the integrin with a compound of formula I or a pharmaceutically acceptable salt thereof. In general formula I, the ring may have any configuration, Z is sulfur, oxygen, CH 2 , NH, NR A or hydrogen, and when Z is hydrogen, R 1 is present R A is selected from the group defined for R 1 to R 5 , X is oxygen or NR A provided that at least one of the X's of general formula I is NR A and X is May independently combine with one of R 1 to R 5 to form an azide, where R 1 to R 5 are independently H, — (CO) R 6 , or a number of 1 to 20 atoms Selected from the group comprising an optionally substituted, branched or straight chain alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituent, wherein the substituent is Is further substituted depending on At best, R 6 in the above formula, the atoms 1 to 20, which is optionally substituted, branched or straight chain alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl Or selected from the group comprising heteroarylalkyl substituents, the substituents optionally further substituted, wherein XR 2 or XR 3 or XR 4 or XR 5 is not NH 2 Furthermore, if at least one of R 2 to R 5 is hydrogen, and the group X is NR A and R A is not hydrogen, then from the group R A and the corresponding group R 2 R 5 may be bonded to form a ring. |